Skip to main content
Erschienen in: World Journal of Urology 10/2020

24.12.2019 | Original Article

Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis

verfasst von: Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Hisashi Hasumi, Kazuhide Makiyama, Keiichi Kondo, Noboru Nakaigawa, Masahiro Yao, Yuki Mukai, Madoka Sugiura, Shoko Takano, Eiko Ito, Hisashi Kaizu, Izumi Koike, Masaharu Hata, Masataka Taguri, Yasuhide Miyoshi, Koji Izumi, Takashi Kawahara, Hiroji Uemura

Erschienen in: World Journal of Urology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To compare the outcomes of radical prostatectomy (RP), intensity-modulated radiation therapy (IMRT), and low-dose-rate brachytherapy (BT) using propensity score matching analysis in patients with clinically localized prostate cancer.

Methods

A group of 2273 patients with clinically localized prostate cancer between January 2004 and December 2015 at the Yokohama City University hospital were identified. The records of 1817 of these patients, who were followed up for a minimum of 2 years, were reviewed; 462 were treated with RP, 319 with IMRT, and 1036 with BT. The patients were categorized according to the National Comprehensive Cancer Network risk classification criteria, and biochemical outcomes and overall survival rates were examined. Biochemical failure for RP was defined as prostate-specific antigen (PSA) levels > 0.2 ng/ml, and for IMRT and BT as nadir PSA level + 2 ng/ml. Propensity scores were calculated using multivariable logistic regression based on covariates, including the patient's age, preoperative PSA, Gleason score, number of positive cores, and clinical T stage.

Results

Median follow-up was 77 months for the RP, 54 months for IMRT, and 66 months for BT patients. After the propensity scores were adjusted, a total of 372 (186 each) and 598 (299 each) patients were categorized into RP vs IMRT and RP vs BT groups, respectively. Kaplan–Meier analysis did not show any statistically significant differences in terms of overall survival rate between these groups (RP vs IMRT: p = 0.220; RP vs BT: p = 0.429). IMRT was associated with improved biochemical failure-free survival compared to RP in all risk groups (high-risk: p < 0.001; intermediate-risk: p = 0.009; low-risk: p = 0.001), whereas significant differences were observed only in the intermediate-risk group (p = 0.003) within the RP vs BT group.

Conclusion

The results of our propensity score analysis of mid-term localized prostate cancer treatment outcomes demonstrated no significant differences in the overall survival rate. Despite the difference in biochemical failure definition between surgery and radiotherapeutic approaches, the results of this study demonstrate improved biochemical control favoring IMRT and BT as compared to RP.
Literatur
1.
Zurück zum Zitat Ye D-W, Zhu Y, Wang H-K, Qu Y-Y (2015) Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl 17:48–57CrossRef Ye D-W, Zhu Y, Wang H-K, Qu Y-Y (2015) Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl 17:48–57CrossRef
3.
Zurück zum Zitat Wallis CJD et al (2016) Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70:21–30CrossRef Wallis CJD et al (2016) Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70:21–30CrossRef
4.
Zurück zum Zitat Hamdy FC et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415–1424CrossRef Hamdy FC et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415–1424CrossRef
5.
Zurück zum Zitat Wilt TJ et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213CrossRef Wilt TJ et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213CrossRef
6.
Zurück zum Zitat Bill-Axelson A et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708–1717CrossRef Bill-Axelson A et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708–1717CrossRef
7.
Zurück zum Zitat Hayashi N et al (2015) Ten-year outcomes of I(125) low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan. World J Urol 33(10):1519–1526CrossRef Hayashi N et al (2015) Ten-year outcomes of I(125) low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan. World J Urol 33(10):1519–1526CrossRef
8.
Zurück zum Zitat Akakura K et al (2006) A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 36:789–793CrossRef Akakura K et al (2006) A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 36:789–793CrossRef
9.
Zurück zum Zitat Paulson DF, Lin GH, Hinshaw W, Stephani S (1982) Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128:502–504CrossRef Paulson DF, Lin GH, Hinshaw W, Stephani S (1982) Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128:502–504CrossRef
10.
Zurück zum Zitat Kibel AS et al (2012) Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 187:1259–1265CrossRef Kibel AS et al (2012) Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 187:1259–1265CrossRef
11.
Zurück zum Zitat Donovan JL et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375:1425–1437CrossRef Donovan JL et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375:1425–1437CrossRef
12.
Zurück zum Zitat Spratt DE et al (2017) American Brachytherapy Society Task Group Report: combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 16:1–12CrossRef Spratt DE et al (2017) American Brachytherapy Society Task Group Report: combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 16:1–12CrossRef
13.
Zurück zum Zitat Cooperberg MR, Vickers AJ, Broering JM, Carroll PR (2010) Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226–5234CrossRef Cooperberg MR, Vickers AJ, Broering JM, Carroll PR (2010) Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226–5234CrossRef
14.
Zurück zum Zitat Hoffman RM et al (2013) Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst 105:711–718CrossRef Hoffman RM et al (2013) Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst 105:711–718CrossRef
15.
Zurück zum Zitat Nepple KG et al (2013) Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol 64:372–378CrossRef Nepple KG et al (2013) Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol 64:372–378CrossRef
16.
Zurück zum Zitat Sooriakumaran P et al (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348:g1502CrossRef Sooriakumaran P et al (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348:g1502CrossRef
17.
Zurück zum Zitat Morris WJ et al (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost. Int J Radiat Oncol Biol Phys 98:275–285CrossRef Morris WJ et al (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost. Int J Radiat Oncol Biol Phys 98:275–285CrossRef
18.
Zurück zum Zitat Kishan AU et al (2016) Clinical outcomes for patients with Gleason score 9–10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis. Eur Urol 71(5):766–773CrossRef Kishan AU et al (2016) Clinical outcomes for patients with Gleason score 9–10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis. Eur Urol 71(5):766–773CrossRef
19.
Zurück zum Zitat Okamoto K, Wada A, Kohno N (2017) High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer. J Contemp Brachyther 9:1–6CrossRef Okamoto K, Wada A, Kohno N (2017) High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer. J Contemp Brachyther 9:1–6CrossRef
20.
Zurück zum Zitat Kalbasi A et al (2015) Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol 1:897CrossRef Kalbasi A et al (2015) Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol 1:897CrossRef
21.
Zurück zum Zitat Zietman AL et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294:1233CrossRef Zietman AL et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294:1233CrossRef
22.
Zurück zum Zitat Miki K et al (2010) Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 10:572CrossRef Miki K et al (2010) Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 10:572CrossRef
23.
Zurück zum Zitat Konaka H et al (2012) Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 12:110CrossRef Konaka H et al (2012) Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 12:110CrossRef
24.
Zurück zum Zitat Saito S, Nagata H, Kosugi M, Toya K, Yorozu A (2007) Brachytherapy with permanent seed implantation. Int J Clin Oncol 12:395–407CrossRef Saito S, Nagata H, Kosugi M, Toya K, Yorozu A (2007) Brachytherapy with permanent seed implantation. Int J Clin Oncol 12:395–407CrossRef
25.
Zurück zum Zitat van Tol-Geerdink JJ et al (2013) Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 111:564–573CrossRef van Tol-Geerdink JJ et al (2013) Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 111:564–573CrossRef
26.
Zurück zum Zitat Koo KC et al (2017) Cancer-specific mortality among korean men with localized or locally advanced prostate cancer treated with radical prostatectomy versus radiotherapy: a multi-center study using propensity scoring and competing risk regression analyses. Cancer Res Treat 50(1):129–137CrossRef Koo KC et al (2017) Cancer-specific mortality among korean men with localized or locally advanced prostate cancer treated with radical prostatectomy versus radiotherapy: a multi-center study using propensity scoring and competing risk regression analyses. Cancer Res Treat 50(1):129–137CrossRef
Metadaten
Titel
Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis
verfasst von
Narihiko Hayashi
Kimito Osaka
Kentaro Muraoka
Hisashi Hasumi
Kazuhide Makiyama
Keiichi Kondo
Noboru Nakaigawa
Masahiro Yao
Yuki Mukai
Madoka Sugiura
Shoko Takano
Eiko Ito
Hisashi Kaizu
Izumi Koike
Masaharu Hata
Masataka Taguri
Yasuhide Miyoshi
Koji Izumi
Takashi Kawahara
Hiroji Uemura
Publikationsdatum
24.12.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 10/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-03056-3

Weitere Artikel der Ausgabe 10/2020

World Journal of Urology 10/2020 Zur Ausgabe

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.